Auro Laboratories Limited

BSE:530233 Stock Report

Market Cap: ₹1.8b

Auro Laboratories Past Earnings Performance

Past criteria checks 4/6

Auro Laboratories has been growing earnings at an average annual rate of 1.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 1.8% per year. Auro Laboratories's return on equity is 14.4%, and it has net margins of 16%.

Key information

1.9%

Earnings growth rate

1.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate1.8%
Return on equity14.4%
Net Margin16.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Auro Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:530233 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2438962550
30 Jun 2449278540
31 Mar 2453678510
31 Dec 2355172440
30 Sep 2352748430
30 Jun 2351931440
31 Mar 2352924470
31 Dec 2257311520
30 Sep 2253814560
30 Jun 2251519600
31 Mar 2250928620
31 Dec 2146539620
30 Sep 2147553620
30 Jun 2152669610
31 Mar 2154372600
31 Dec 2050161610
30 Sep 2046651590
30 Jun 2042343550
31 Mar 2043841530
31 Dec 1945952470
30 Sep 1948655430
30 Jun 1950149420
31 Mar 1946844410
31 Dec 1846637450
30 Sep 1846636420
30 Jun 1843737380
31 Mar 1840835370
31 Dec 1739632320
30 Sep 1734620310
30 Jun 1733014320
31 Mar 173558310
31 Dec 1633115270
30 Sep 1634414270
30 Jun 1631413260
31 Mar 162799250
31 Dec 152888430
30 Sep 152858430
30 Jun 153238230
31 Mar 153268220
31 Dec 143015330
30 Sep 143005320
30 Jun 143045390
31 Mar 143376340
31 Dec 134677210

Quality Earnings: 530233 has a high level of non-cash earnings.

Growing Profit Margin: 530233's current net profit margins (16%) are higher than last year (9.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 530233's earnings have grown by 1.9% per year over the past 5 years.

Accelerating Growth: 530233's earnings growth over the past year (29.1%) exceeds its 5-year average (1.9% per year).

Earnings vs Industry: 530233 earnings growth over the past year (29.1%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 530233's Return on Equity (14.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Auro Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution